Answers are grounded in this paper and cite their sources.
To characterize real-world treatment patterns and outcomes in nodal peripheral T-cell lymphoma (PTCL) and to develop and externally validate a contemporary clinical prognostic model, we analyzed patients prospectively registered in the International T-Cell Project 2 (TCP2). Between January 2018 and January 2026, 1,465 patients with PTCL were registered; 959 with nodal PTCL by the 2016 WHO classification (PTCL not otherwise specified (PTCL-NOS), systemic anaplastic large-cell lymphoma (ALCL; ALK-positive or ALK-negative), and T-follicular helper lymphoma (TFHL)) were analyzed. The primary endpoint was 2-year progression-free survival (PFS); the model was externally validated in the TCP1 cohort (n = 1,016). The cohort comprised 396 PTCL-NOS (41%), 263 TFHL (27%), 211 ALK-negative ALCL (22%), and 89 ALK-positive ALCL (9%). First-line therapy was CHOEP in 340 (37%), CHOP in 260 (29%), and brentuximab vedotin-CHP in 139 (15%); 156 underwent consolidative stem cell transplantation. After a median follow-up of 25.3 months, 2-year PFS and overall survival were 35.3% and 54.3%, respectively. In multivariate analysis, diagnosis other than ALCL, age ≥65 years, ECOG performance status ≥2, thrombocytopenia, extranodal involvement, and elevated LDH were independently associated with inferior PFS. A six-variable score using these factors stratified patients into 3 risk groups - low (score 0-1), intermediate (2-3), and high (4-6) with 2-year PFS, 65%, 33%, and 16% respectively (P < .001) and was confirmed in the TCP1 validation cohort. Outcomes for nodal PTCL remain poor with current therapy; the externally validated TCP score offers a contemporary, complementary tool for risk stratification and identification of patients at high risk of treatment failure. ClinicalTrials.gov NCT03964480, NCT01142674
No takes yet. Share an insight, caveat, or question.
Luminari et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: